Massive Bio, a New York-based developer of an AI-driven oncology platform focusing on connecting cancer patients to available biopharmaceutical clinical trials, has partnered with Un Ensayo Para Mi (UEPM), a developer of a clinical trial search platform to extend better access to clinical trials by cancer patients in Latin America.
The partnership announced during ASCO24, will help extend Massive Bio’s presence to nine Latin American countries, including Argentina, Brazil, Mexico, and Colombia, improving access to clinical trials and patient care. By leveraging UEPM’s AI-backed technology and vast network, Massive Bio aims to ensure more clients in LATAM access its cutting-edge platform.
According to Massive Bio’s Co-Founder and CEO, Dr. Selin Kurnaz, the latest collaboration with UEPM is a step toward democratizing access to clinical trials for cancer patients in LATAM and other regions globally. This will help narrow the gap between innovative oncology care and patients who mostly require them.
Un Ensayo Para Mi views the partnership as an opportunity to leverage its AI-powered search platform to help patients find clinical trials matching their specific medical conditions and care needs. By integrating Massive Bio’s cutting-edge solutions into its platform, UEPM looks to provide more accurate, precise, and timely clinical trial matches, boosting participation rates and accelerating cancer research.
With a shared mission of supporting physicians, helping cancer patients, advancing research in the oncology space, and transforming Latin America into a new hub for cancer treatment innovations, the two medical tech giants are looking to rapidly improve accessibility and efficiency of finding appropriate clinical trials for cancer patients.